

Supplementary Table I: Characteristics of MOLM-13, SKM-1 and THP-1 cell lines ^{1,2}

Cell line	Cell type	Description	FAB subtype	HLA genotyping	Cytogenetics	Mutations
MOLM-13	acute myeloid leukemia	established from the peripheral blood of a 20-year-old man, following myelodysplastic syndrome (MDS)	M5	HLA-A*26:01	52, XY, del(2)(q22.3q22.3), 16, 18, 18, 1del(8)(p11.1p23.3), ins(11;9)(q11;p21.3p21.3)*, 113, dup(17)(q11.2q11.2), 119, dup(20)(p11.1p13)	BCOR; FLT3; KMT2A; NF1
				HLA-A*31:01		
				HLA-B*44:03		
				HLA-B*51:01		
				HLA-C*14:02		
SKM-1	acute myeloid leukemia	established from the peripheral blood of a 76-year-old man, following MDS	M5	HLA-C*14:03	45, XY, dup(2)(p11.2p12), dup(4)(p15.33p16.3), del(4)(q22.1q22.1), del(6)(p22.3p22.3), del(7)(q35q36.3), 1dup(8)(q23.3q24.3), dup(8)(q24.3q24.3), del(9)(p21.1p21.1), del(9)(q21.11q33.1), der(10)(4p16.34p15.33::10p15.1p15.3::10p11.11qter), -12, del(13)(q13.3q14.11), -14, del(16)(p13.3), del(16)(q23.1), del(16)(q23.1q23.2), del(16)(q24.3), del(17)(p12p13.3), del(18)(p11.23p11.23), del(18)(q11.2q11.2), der(19)t(1;19)(q21.1;q13.2), del(20)(p11.23p13), der(22)t(2;22)(p11.2;p11)	ASXL1; BCORL1; EZH2; SF1; STAG2; TET2; TP53; WT1
				HLA-A*02:07		
				HLA-A*33:03		
				HLA-B*40:01		
				HLA-B*59:01		
THP-1	acute monocytic leukemia	established from the peripheral blood of a 1-year-old boy	M5	HLA-C*01:02	49,XY,1der(1)del(1)(p22p36)t(1;12)(p36;q11),del(6)(p21),1del(6)(p21),18,1der(9)t(9;11)(p22;q23)t(9;11)(q12;q23),210,der(11)t(9;11)(p22;q23),del(12)(q11),del(17)(p11),der(20)- ins(20;1)(p12;p22p36)	KMT2A-MLLT3 (MLL-MLLT3; MLL-AF9) fusion gene
				HLA-C*03:04		
				HLA-A*02:01		
				HLA-A*24:02		
				HLA-B*15:11		
				HLA-B*35:01		
				HLA-C*03:03		

- 1.Odero, M.D., Zeleznik-Le, N.J., Chinwalla, V. & Rowley, J.D. Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation. *Genes Chromosomes Cancer* **29**, 333-338 (2000).
- 2.Palau, A., *et al.* Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. *Genes Chromosomes Cancer* **56**, 243-252 (2017).